CliffBio
biologic

Avonex

interferon beta-1a

Loss of exclusivityFebruary 2024projected — 12-year biologic exclusivity estimate
CompanyBiogen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAvonex
Active ingredientinterferon beta-1a
Strength30MCG/0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2012
Marketing statusRx

More from Biogen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Avonex patent cliff — loss of exclusivity February 2024 | CliffBio